Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy.

Journal Article (Journal Article;Review)

BACKGROUND AND OBJECTIVE: The purpose of this article is to review the role of anti-vascular endothelial growth factor (VEGF) therapy in treating patients with radiation retinopathy (RR). PATIENTS AND METHODS: RR can be associated with a significant decrease in visual acuity (VA) related to the development of cystoid macular edema, macular ischemia, and proliferative retinopathy leading to neovascular glaucoma. RESULTS: Anti-VEGF therapy is effective at stabilizing VA in around 80% of patients and achieving reductions in central macular thickness when it is administered using a constant algorithm. Furthermore, consistent prophylactic anti-VEGF therapy reduces the risk of development of RR, neovascularization of the iris, and neovascularization glaucoma. CONCLUSION: Future studies are needed to determine the optimal regimen for anti-VEGF therapy according to patient risk factors and likelihood of developing RR. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:S44-S49.].

Full Text

Duke Authors

Cited Authors

  • Rayess, N; Mruthyunjaya, P

Published Date

  • April 1, 2020

Published In

Volume / Issue

  • 51 / 4

Start / End Page

  • S44 - S49

PubMed ID

  • 32348534

Electronic International Standard Serial Number (EISSN)

  • 2325-8179

Digital Object Identifier (DOI)

  • 10.3928/23258160-20200401-06

Language

  • eng

Conference Location

  • United States